Middle East & Africa Human Vaccine Market Research Report Information by Vaccine Type (Inactivated, Toxoid, Conjugate and Subunit, Recombinant DNA), by Age Group (Pediatrics, and Adults), by Indication (Pneumococcal, Influenza, Hepatitis, DTP, Polio and others), by Route of Administration (Injectable, Oral, and others), by Distribution Channel (Public, and Private) Forecast to 2032
Overview of the Market
During the review period, the human vaccine market in the Middle East and Africa is expected to grow at a compound annual growth rate (CAGR) of 8.80%. Human vaccinations are biological preparations that protect people from illness and its potentially serious effects by inducing immunity to a particular disease in the immune system. To elicit an immune response without actually causing the disease, these vaccines usually contain pathogens (such bacteria or viruses), their toxins, or surface proteins that have been weakened or destroyed.
The market for human vaccines in the Middle East and Africa is expanding due to rising disease burden, epidemic outbreaks, and growing knowledge of the value of vaccination in avoiding infectious illnesses. Furthermore, the industry will have future growth prospects due to the growing finance and investment for expansion.
Market Segment Insights
The human vaccination market in the Middle East and Africa has been divided into four segments based on the kind of vaccine: inactivated, toxoid, conjugate and subunit, and recombinant DNA.
The human vaccine market in the Middle East and Africa has been divided into two age groups: adults and pediatrics. Throughout the projected period, the pediatrics sector grew at the highest rate and held the largest market in 2023.
The human vaccine market in the Middle East and Africa has been divided into segments based on indications, including polio, DTP, hepatitis, influenza, and pneumococcal.
The human vaccine market in the Middle East and Africa has been divided into injectable, oral, and other segments based on the route of administration.
The human vaccine market in the Middle East and Africa has been divided into two segments based on the distribution channel: public and private.
The market for human vaccines in the Middle East, which is further divided into the United Arab Emirates, Saudi Arabia, Israel, Kuwait, Oman, Qatar, Egypt, Bahrain, and the Rest of the Middle East, was worth USD Egypt million in 2023.
The market for human vaccines in the Middle East is expected to increase significantly due to rising healthcare costs, growing government backing for the vaccine, and growing awareness of its significance. The Kingdom of Saudi Arabia committed to funding the Global Polio Eradication Initiative (GPEI) with $500 million over five years in April 2024. The launch of novel vaccinations that target a wider variety of diseases and improvements in vaccine technology further support the market's growth. To fight newly developing infectious diseases, current trends point to a move toward customized vaccinations and higher spending on research and development.
Key Players
Pfizer Inc., Merck & Co., Inc., AstraZeneca, Bharat Biotech, SaudiVax, Biovac, Vacsera, Cipla, GSK Plc, and Sanofi are the major companies in the Middle East human vaccine market.
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 35
TABLE 2 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 49
TABLE 3 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 50
TABLE 4 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR INACTIVATED, BY REGION, 2019–2032 (USD MILLION) 50
TABLE 5 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR TOXOID, BY REGION, 2019–2032 (USD MILLION) 51
TABLE 6 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR CONJUGATE AND SUBUNIT, BY REGION, 2019–2032 (USD MILLION) 51
TABLE 7 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR RECOMBINANT DNA, BY REGION, 2019–2032 (USD MILLION) 51
TABLE 8 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 53
TABLE 9 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR PEDIATRICS, BY REGION, 2019–2032 (USD MILLION) 54
TABLE 10 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR ADULTS, BY REGION, 2019–2032 (USD MILLION) 54
TABLE 11 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 56
TABLE 12 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 57
TABLE 13 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR PNEUMOCOCCAL, BY REGION, 2019–2032 (USD MILLION) 58
TABLE 14 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR INFLUENZA, BY REGION, 2019–2032 (USD MILLION) 58
TABLE 15 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS, BY REGION, 2019–2032 (USD MILLION) 58
TABLE 16 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 59
TABLE 17 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 59
TABLE 18 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS A, BY REGION, 2019–2032 (USD MILLION) 59
TABLE 19 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HEPATITIS B, BY REGION, 2019–2032 (USD MILLION) 60
TABLE 20 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR DTP, BY REGION, 2019–2032 (USD MILLION) 60
TABLE 21 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR POLIO, BY REGION, 2019–2032 (USD MILLION) 61
TABLE 22 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 61
TABLE 23 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 61
TABLE 24 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR INACTIVATED POLIO VACCINE (IPV), BY REGION, 2019–2032 (USD MILLION) 62
TABLE 25 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR ORAL POLIO VACCINE (OPV), BY REGION, 2019–2032 (USD MILLION) 62
TABLE 26 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR HUMAN PAPILLOMAVIRUS, BY REGION, 2019–2032 (USD MILLION) 62
TABLE 27 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR MENINGOCOCCAL, BY REGION, 2019–2032 (USD MILLION) 63
TABLE 28 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 65
TABLE 29 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR INJECTABLE, BY REGION, 2019–2032 (USD MILLION) 67
TABLE 30 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR ORAL, BY REGION, 2019–2032 (USD MILLION) 67
TABLE 31 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 67
TABLE 32 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 69
TABLE 33 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR PUBLIC, BY REGION, 2019–2032 (USD MILLION) 70
TABLE 34 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, FOR PRIVATE, BY REGION, 2019–2032 (USD MILLION) 70
TABLE 35 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY REGION, 2019–2032 (USD MILLION) 71
TABLE 36 MIDDLE EAST HUMAN VACCINE MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 74
TABLE 37 MIDDLE EAST: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019–2032 (USD MILLION) 75
TABLE 38 MIDDLE EAST: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019–2032 (VOLUME) 76
TABLE 39 MIDDLE EAST: HUMAN VACCINE MARKET, BY AGE GROUP 2019–2032 (USD MILLION) 76
TABLE 40 MIDDLE EAST: HUMAN VACCINE MARKET, BY INDICATION 2019–2032 (USD MILLION) 76
TABLE 41 MIDDLE EAST: HUMAN VACCINE MARKET, BY INDICATION 2019–2032 (VOLUME) 77
TABLE 42 MIDDLE EAST: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019–2032 (USD MILLION) 77
TABLE 43 MIDDLE EAST: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019–2032 (VOLUME) 77
TABLE 44 MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019–2032 (USD MILLION) 78
TABLE 45 MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019–2032 (VOLUME) 78
TABLE 46 MIDDLE EAST: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019–2032 (USD MILLION) 78
TABLE 47 MIDDLE EAST: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019–2032 (USD MILLION) 79
TABLE 48 UAE: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019–2032 (USD MILLION) 79
TABLE 49 UAE: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019–2032 (VOLUME) 79
TABLE 50 UAE: HUMAN VACCINE MARKET, BY AGE GROUP 2019–2032 (USD MILLION) 80
TABLE 51 UAE: HUMAN VACCINE MARKET, BY INDICATION 2019–2032 (USD MILLION) 80
TABLE 52 UAE: HUMAN VACCINE MARKET, BY INDICATION 2019–2032 (VOLUME) 81
TABLE 53 UAE: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019–2032 (USD MILLION) 81
TABLE 54 UAE: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019–2032 (VOLUME) 81
TABLE 55 UAE: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019–2032 (USD MILLION) 82
TABLE 56 UAE: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019–2032 (VOLUME) 82
TABLE 57 UAE: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019–2032 (USD MILLION) 82
TABLE 58 UAE: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019–2032 (USD MILLION) 83
TABLE 59 SAUDI ARABIA: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019–2032 (USD MILLION) 83
TABLE 60 SAUDI ARABIA: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019–2032 (VOLUME) 83
TABLE 61 SAUDI ARABIA: HUMAN VACCINE MARKET, BY AGE GROUP 2019–2032 (USD MILLION) 84
TABLE 62 SAUDI ARABIA: HUMAN VACCINE MARKET, BY INDICATION 2019–2032 (USD MILLION) 84
TABLE 63 SAUDI ARABIA: HUMAN VACCINE MARKET, BY INDICATION 2019–2032 (VOLUME) 85
TABLE 64 SAUDI ARABIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019–2032 (USD MILLION) 85
TABLE 65 SAUDI ARABIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019–2032 (VOLUME) 85
TABLE 66 SAUDI ARABIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019–2032 (USD MILLION) 86
TABLE 67 SAUDI ARABIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019–2032 (VOLUME) 86
TABLE 68 SAUDI ARABIA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019–2032 (USD MILLION) 86
TABLE 69 SAUDI ARABIA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019–2032 (USD MILLION) 87
TABLE 70 ISRAEL: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019–2032 (USD MILLION) 87
TABLE 71 ISRAEL: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019–2032 (VOLUME) 88
TABLE 72 ISRAEL: HUMAN VACCINE MARKET, BY AGE GROUP 2019–2032 (USD MILLION) 88
TABLE 73 ISRAEL: HUMAN VACCINE MARKET, BY INDICATION 2019–2032 (USD MILLION) 88
TABLE 74 ISRAEL: HUMAN VACCINE MARKET, BY INDICATION 2019–2032 (VOLUME) 89
TABLE 75 ISRAEL: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019–2032 (USD MILLION) 89
TABLE 76 ISRAEL: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019–2032 (VOLUME) 89
TABLE 77 ISRAEL: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019–2032 (USD MILLION) 90
TABLE 78 ISRAEL: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019–2032 (VOLUME) 90
TABLE 79 ISRAEL: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019–2032 (USD MILLION) 90
TABLE 80 ISRAEL: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019–2032 (USD MILLION) 91
TABLE 81 KUWAIT: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019–2032 (USD MILLION) 91
TABLE 82 KUWAIT: HUMAN VACCINE MARKET, BY VACCINE TYPE 2019–2032 (VOLUME) 91
TABLE 83 KUWAIT: HUMAN VACCINE MARKET, BY AGE GROUP 2019–2032 (USD MILLION) 92
TABLE 84 KUWAIT: HUMAN VACCINE MARKET, BY INDICATION 2019–2032 (USD MILLION) 92
TABLE 85 KUWAIT: HUMAN VACCINE MARKET, BY INDICATION 2019–2032 (VOLUME) 93
TABLE 86 KUWAIT: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019–2032 (USD MILLION) 93
TABLE 87 KUWAIT: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE 2019–2032 (VOLUME) 93
TABLE 88 KUWAIT: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019–2032 (USD MILLION) 94
TABLE 89 KUWAIT: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE 2019–2032 (VOLUME) 94
TABLE 90 KUWAIT: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 2019–2032 (USD MILLION) 94
TABLE 91 KUWAIT: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL 2019–2032 (USD MILLION) 95
TABLE 92 OMAN: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 96
TABLE 93 OMAN: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 96
TABLE 94 OMAN: HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 96
TABLE 95 OMAN: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 97
TABLE 96 OMAN: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 97
TABLE 97 OMAN: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 97
TABLE 98 OMAN: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 98
TABLE 99 OMAN: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 98
TABLE 100 OMAN: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 98
TABLE 101 OMAN: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 98
TABLE 102 OMAN: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 99
TABLE 103 QATAR: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 99
TABLE 104 QATAR: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 99
TABLE 105 QATAR: HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 100
TABLE 106 QATAR: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 100
TABLE 107 QATAR: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 100
TABLE 108 QATAR: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 101
TABLE 109 QATAR: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 101
TABLE 110 QATAR: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 101
TABLE 111 QATAR: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 101
TABLE 112 QATAR: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 102
TABLE 113 QATAR: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 102
TABLE 114 EGYPT: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 102
TABLE 115 EGYPT: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 103
TABLE 116 EGYPT: HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 103
TABLE 117 EGYPT: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 103
TABLE 118 EGYPT: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 104
TABLE 119 EGYPT: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 104
TABLE 120 EGYPT: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 104
TABLE 121 EGYPT: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 105
TABLE 122 EGYPT: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 105
TABLE 123 EGYPT: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 105
TABLE 124 EGYPT: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 105
TABLE 125 BAHRAIN: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 106
TABLE 126 BAHRAIN: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 106
TABLE 127 BAHRAIN: HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 106
TABLE 128 BAHRAIN: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 107
TABLE 129 BAHRAIN: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 107
TABLE 130 BAHRAIN: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 107
TABLE 131 BAHRAIN: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 108
TABLE 132 BAHRAIN: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 108
TABLE 133 BAHRAIN: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 108
TABLE 134 BAHRAIN: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 108
TABLE 135 BAHRAIN: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 109
TABLE 136 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 109
TABLE 137 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 109
TABLE 138 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 110
TABLE 139 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 110
TABLE 140 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 110
TABLE 141 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 111
TABLE 142 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 111
TABLE 143 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 111
TABLE 144 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 111
TABLE 145 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 112
TABLE 146 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 112
TABLE 147 AFRICA: HUMAN VACCINE MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 115
TABLE 148 AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 116
TABLE 149 AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 116
TABLE 150 AFRICA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 116
TABLE 151 AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 117
TABLE 152 AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 117
TABLE 153 AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 117
TABLE 154 AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 118
TABLE 155 AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 118
TABLE 156 REST OF MIDDLE EAST: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 118
TABLE 157 AFRICA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 118
TABLE 158 AFRICA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 119
TABLE 159 KENYA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 119
TABLE 160 KENYA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 119
TABLE 161 KENYA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 120
TABLE 162 KENYA: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 120
TABLE 163 KENYA: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 120
TABLE 164 KENYA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 121
TABLE 165 KENYA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 121
TABLE 166 KENYA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 121
TABLE 167 KENYA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 121
TABLE 168 KENYA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 122
TABLE 169 KENYA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 122
TABLE 170 SOUTH AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 122
TABLE 171 SOUTH AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 123
TABLE 172 SOUTH AFRICA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 123
TABLE 173 SOUTH AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 123
TABLE 174 SOUTH AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 124
TABLE 175 SOUTH AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 124
TABLE 176 SOUTH AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 124
TABLE 177 SOUTH AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 125
TABLE 178 SOUTH AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 125
TABLE 179 SOUTH AFRICA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 125
TABLE 180 SOUTH AFRICA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 125
TABLE 181 NIGERIA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 126
TABLE 182 NIGERIA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 126
TABLE 183 NIGERIA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 126
TABLE 184 NIGERIA: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 127
TABLE 185 NIGERIA: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 127
TABLE 186 NIGERIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 127
TABLE 187 NIGERIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 128
TABLE 188 NIGERIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 128
TABLE 189 NIGERIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 128
TABLE 190 NIGERIA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 128
TABLE 191 NIGERIA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 129
TABLE 192 MOZAMBIQUE: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 129
TABLE 193 MOZAMBIQUE: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 129
TABLE 194 MOZAMBIQUE: HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 130
TABLE 195 MOZAMBIQUE: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 130
TABLE 196 MOZAMBIQUE: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 130
TABLE 197 MOZAMBIQUE: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 131
TABLE 198 MOZAMBIQUE: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 131
TABLE 199 MOZAMBIQUE: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 131
TABLE 200 MOZAMBIQUE: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 131
TABLE 201 MOZAMBIQUE: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 132
TABLE 202 MOZAMBIQUE: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 132
TABLE 203 TANZANIA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 132
TABLE 204 TANZANIA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 133
TABLE 205 TANZANIA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 133
TABLE 206 TANZANIA: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 133
TABLE 207 TANZANIA: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 134
TABLE 208 TANZANIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 134
TABLE 209 TANZANIA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 134
TABLE 210 TANZANIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 135
TABLE 211 TANZANIA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 135
TABLE 212 TANZANIA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 135
TABLE 213 TANZANIA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 135
TABLE 214 UGANDA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 136
TABLE 215 UGANDA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 136
TABLE 216 UGANDA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 136
TABLE 217 UGANDA: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 137
TABLE 218 UGANDA: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 137
TABLE 219 UGANDA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 137
TABLE 220 UGANDA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 138
TABLE 221 UGANDA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 138
TABLE 222 UGANDA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 138
TABLE 223 UGANDA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 138
TABLE 224 UGANDA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 139
TABLE 225 MOROCCO: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 139
TABLE 226 MOROCCO: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 139
TABLE 227 MOROCCO: HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 140
TABLE 228 MOROCCO: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 140
TABLE 229 MOROCCO: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 140
TABLE 230 MOROCCO: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 141
TABLE 231 MOROCCO: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 141
TABLE 232 MOROCCO: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 141
TABLE 233 MOROCCO: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 141
TABLE 234 MOROCCO: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 142
TABLE 235 MOROCCO: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 142
TABLE 236 REST OF AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (USD MILLION) 143
TABLE 237 REST OF AFRICA: HUMAN VACCINE MARKET, BY VACCINE TYPE, 2019–2032 (VOLUME) 143
TABLE 238 REST OF AFRICA: HUMAN VACCINE MARKET, BY AGE GROUP, 2019–2032 (USD MILLION) 143
TABLE 239 REST OF AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (USD MILLION) 144
TABLE 240 REST OF AFRICA: HUMAN VACCINE MARKET, BY INDICATION, 2019–2032 (VOLUME) 144
TABLE 241 REST OF AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (USD MILLION) 144
TABLE 242 REST OF AFRICA: HUMAN VACCINE MARKET, FOR HEPATITIS, BY TYPE, 2019–2032 (VOLUME) 145
TABLE 243 REST OF AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (USD MILLION) 145
TABLE 244 REST OF AFRICA: HUMAN VACCINE MARKET, FOR POLIO, BY TYPE, 2019–2032 (VOLUME) 145
TABLE 245 REST OF AFRICA: HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION) 145
TABLE 246 REST OF AFRICA: HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2019–2032 (USD MILLION) 146
TABLE 247 PRODUCT LAUNCH/PRODUCT APPROVAL 151
TABLE 248 AGREEMENT/COLLABORATION/PARTNERSHIP 151
TABLE 249 SANOFI: PRODUCTS OFFERED 153
TABLE 250 SANOFI: KEY DEVELOPMENTS 154
TABLE 251 BHARAT BIOTECH: PRODUCT OFFERED 157
TABLE 252 BHARAT BIOTECH: KEY DEVELOPMENTS 157
TABLE 253 PFIZER INC: PRODUCT OFFERED 159
TABLE 254 PFIZER INC: KEY DEVELOPMENTS 160
TABLE 255 MERCK & CO., INC.: PRODUCTS OFFERED 164
TABLE 256 ASTRAZENECA: PRODUCT OFFERED 166
TABLE 257 CIPLA: PRODUCTS OFFERED 169
TABLE 258 SAUDIVAX: PRODUCTS OFFERED 172
TABLE 259 GSK PLC: PRODUCTS OFFERED 175
TABLE 260 GSK PLC: KEY DEVELOPMMENTS 175
TABLE 261 BIOVAC: PRODUCTS OFFERED 178
TABLE 262 VACSERA: PRODUCTS OFFERED 179
LIST OF FIGURES
FIGURE 1 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET: STRUCTURE 23
FIGURE 2 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032) 39
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 41
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032) 42
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: MIDDLE EAST & AFRICA HUMAN VACCINE MARKET 44
FIGURE 6 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, VACCINE TYPE SEGMENT, 2023 & 2032 (USD MILLION) 48
FIGURE 7 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY TYPE, 2023 & 2032 (USD MILLION) 49
FIGURE 8 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY VACCINE TYPE, 2023 50
FIGURE 9 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, AGE-GROUP SEGMENT, 2023 & 2032 (USD MILLION) 52
FIGURE 10 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY AGE GROUP, 2023 & 2032 (USD MILLION) 53
FIGURE 11 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY AGE GROUP, 2023 54
FIGURE 12 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, INDICATION SEGMENT, 2023 & 2032 (USD MILLION) 55
FIGURE 13 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY INDICATION, 2023 & 2032 (USD MILLION) 56
FIGURE 14 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY INDICATION, 2023 57
FIGURE 15 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, ROUTE OF ADMINISTRATION SEGMENT, 2023 & 2032 (USD MILLION) 64
FIGURE 16 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2023 & 2032 (USD MILLION) 65
FIGURE 17 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2023 66
FIGURE 18 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, DISTRIBUTION CHANNEL SEGMENT, 2023 & 2032 (USD MILLION) 68
FIGURE 19 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2032 (USD MILLION) 69
FIGURE 20 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2023 70
FIGURE 21 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY REGION, 2023 & 2032 (USD MILLION) 71
FIGURE 22 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET SHARE, BY REGION, 2023 (% SHARE) 72
FIGURE 23 MIDDLE EAST MARKET ANALYSIS: HUMAN VACCINE MARKET, 2019-2032 (USD MILLION) 73
FIGURE 24 MIDDLE EAST HUMAN VACCINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 74
FIGURE 25 MIDDLE EAST HUMAN VACCINE MARKET, BY COUNTRY, 2023 (% SHARE) 75
FIGURE 26 AFRICA MARKET ANALYSIS: DIGITAL PCR MARKET, 2019-2032 (USD MILLION) 114
FIGURE 27 AFRICA HUMAN VACCINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 114
FIGURE 28 AFRICA HUMAN VACCINE MARKET SHARE, BY COUNTRY, 2023 (%) 115
FIGURE 29 MIDDLE EAST AND AFRICA HUMAN VACCINE MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023 (%) 148
FIGURE 30 COMPETITOR DASHBOARD: MIDDLE EAST AND AFRICA HUMAN VACCINE MARKET 149
FIGURE 31 SANOFI: FINANCIAL OVERVIEW SNAPSHOT 153
FIGURE 32 SANOFI: SWOT ANALYSIS 155
FIGURE 33 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT 159
FIGURE 34 PFIZER INC: SWOT ANALYSIS 160
FIGURE 35 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT 163
FIGURE 36 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 166
FIGURE 37 CIPLA: FINANCIAL OVERVIEW SNAPSHOT 169
FIGURE 38 CIPLA: SWOT ANALYSIS 170
FIGURE 39 GSK PLC: FINANCIAL OVERVIEW SNAPSHOT 174
FIGURE 40 GSK PLC: SWOT ANALYSIS 176
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們